Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.38 |
| ▸ | LTK | P29376 | 3/20 | 0.38 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.38 |
| ▸ | CDK8 | P49336 | 3/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.38 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | CAMK1D | Q8IU85 | 3/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | PRKACA | P17612 | 2/20 | 0.38 |
| ▸ | GRK5 | P34947 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | CLK2 | P49760 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31687183 | 0.86 | TRIM24 (0.36) | CYP2A6DAPK3LTKMAP2K2MAPK8 | |
| SCHEMBL31687193 | 0.86 | TRIM24 (0.36) | CYP2A6DAPK3LTKMAP2K2MAPK8 | |
| SCHEMBL31687191 | 0.86 | TRIM24 (0.36) | CYP2A6DAPK3LTKMAP2K2MAPK8 | |
| SCHEMBL30864883 | 0.86 | TRIM24 (0.36) | CYP2A6DAPK3LTKMAP2K2MAPK8 | |
| SCHEMBL11207953 | 0.83 | CYP2A6 (0.39) | CYP2A6DAPK3LTKMAP2K2MAPK8 | |
| Hydrochloric Acid SCHEMBL11205815 | 0.82 | CYP2A6 (0.38) | CYP2A6DAPK3LTKMAP2K2MAPK8 | |
| SCHEMBL30994991 | 0.80 | TRIM24 (0.39) | DAPK3LTKMAP2K2MAPK8CSNK1A1 | |
| SCHEMBL14123799 | 0.74 | — | — | |
| SCHEMBL28881580 | 0.72 | DAPK3 (0.36) | DAPK3LTKMAP2K2MAPK8CSNK1A1 | |
| SCHEMBL31174052 | 0.69 | PLK1 (0.35) | CCNA2CDK2CCNA1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-4464703-A2 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-4245756-B1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2024-10-09 | — | — | EP | disclosed |
| US-11897862-B2 | IKAROS zinc finger family degraders and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230373950-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230295111-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4245756-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| EP-2892527-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | AbbVie Inc. (US) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014039757-A1 | HETEROCYCLIC NUCLEAR HORMONE RECEPTOR MODULATORS | ABBVIE INC. (US) | 2014-03-13 | — | — | WO | disclosed |
| WO-2011077502-A1 | DIHYDROTHIENO[2,3-E]INDAZOLE COMPOUND | 杏林製薬株式会社 (JP) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358887-B2 | IKAROS Zinc Finger Family degraders and uses thereof | IKZF2, IKZF1, IKZF3 | CYP2A6 3022/4885DAPK3 1638/4885LTK 1389/4885 |
| US-20230373950-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | CYP2A6 3022/4885DAPK3 1638/4885LTK 1389/4885 |
| US-11897862-B2 | IKAROS zinc finger family degraders and uses thereof | IKZF2, IKZF1, IKZF3 | CYP2A6 3022/4885DAPK3 1638/4885LTK 1389/4885 |
| US-20230295111-A1 | IKAROS ZINC FINGER FAMILY DEGRADERS AND USES THEREOF | IKZF2, IKZF1, IKZF3 | CYP2A6 3022/4885DAPK3 1638/4885LTK 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.